Drug Trial Radar · NCT05763550
To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic Neuralgia
Last checked: Nov 20, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
331
Actual
Start
Feb 27, 2023
Primary completion
Jun 22, 2023
Study completion Aug 7, 2023
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigate the efficacy and safety of HSK16149 capsules in Chinese herpetic Neuralgia following 4 weeks treatment in comparison to pregabalin.
Conditions
- Herpetic Neuralgia
Interventions
HSK16149 20mg BIDDrug
HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
HSK16149 40mg BIDDrug
HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.
Pregabalin 150mgDrug
pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week;300 mg (150 mg twice daily) daily for 3 week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare the change from baseline in Numeric Rating Scales(NRS )between HSK16149 and pregabalin at week 4Time frame: Baseline and week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.